Fortress Biotech(FBIO) - 2024 Q2 - Quarterly Results

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to treat metastatic or locally advanced cutaneous squamous cell carcinoma; PDUFA goal date of December 28, 2024 Miami, FL – August 13, 2024 – Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceuti ...